Romuald Girard to Middle Aged
This is a "connection" page, showing publications Romuald Girard has written about Middle Aged.
Connection Strength
0.280
-
Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. 2018 06 08; 122(12):1716-1721.
Score: 0.040
-
Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. 2018 02; 9(1):34-43.
Score: 0.038
-
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. J Neurosurg. 2017 Jul; 127(1):102-110.
Score: 0.036
-
Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016; 10(3):255-64.
Score: 0.034
-
Brain plasticity and neuroinflammatory protein biomarkers with circulating MicroRNAs as predictors of acute brain injury outcome - A prospective cohort study. J Neurol Sci. 2024 Sep 15; 464:123169.
Score: 0.015
-
Pathologic features of brain hemorrhage after radiation treatment: case series with somatic mutation analysis. J Stroke Cerebrovasc Dis. 2024 Jul; 33(7):107699.
Score: 0.015
-
COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. J Stroke Cerebrovasc Dis. 2021 Nov; 30(11):106101.
Score: 0.013
-
Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage. J Cereb Blood Flow Metab. 2021 11; 41(11):2944-2956.
Score: 0.012
-
Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nat Commun. 2020 05 27; 11(1):2659.
Score: 0.012
-
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. J Autoimmun. 2020 09; 113:102469.
Score: 0.012
-
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2021 03 01; 134(3):1147-1154.
Score: 0.011
-
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery. 2019 06 01; 84(6):1157-1168.
Score: 0.011
-
Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III): A Posthoc Root-Cause Analysis. Neurosurgery. 2018 12 01; 83(6):1260-1268.
Score: 0.010
-
Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. AJNR Am J Neuroradiol. 2016 Jul; 37(7):1209-15.
Score: 0.009
-
Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2015 Oct; 35(10):1632-9.
Score: 0.008
-
A study of the practice of otorhinolaryngology in the United States. Initial findings. Arch Otolaryngol. 1979 Oct; 105(10):610-20.
Score: 0.003
-
A study of the practice of dermatology in the United States. Initial findings. Arch Dermatol. 1978 Oct; 114(10):1456-62.
Score: 0.001